With the increasing digitisation of healthcare, real-world data is available in greater quantity and scope than ever before. Harness its rich value with our revolutionary new integration with WEHI, Australia's oldest medical research institute.
Together, Imagine If Health and the Gibbs lab at the WEHI, are working together to enable pharmaceutical and biotech companies to rapidly and efficiently collect structured real-world data (RWD) alongside their oncology and haematology Medicines Access Programs.
RWD is highly valuable in pharmaceutical decision-making, providing companies and healthcare professionals a greater understanding of how patients respond to treatments outside of the strict conditions of clinical trials. Medicines Access Programs provide an avenue for companies to gather rich data across a diverse and less restricted patient population.
Partnering with the experts at the WEHI allows strict governance and academic credibility to collect data appropriately. System integration means that the data can be collected in real time which provides huge advantages to companies looking to leverage this data internally or externally.
Now you can capture the immense value of RWD alongside your active oncology and haematology Medicines Access Programs
Technology can enable the rapid and seamless collection of data better than ever before. Collect rich patient data alongside your MAP, in real-time, to help improve access to medicines.
Imagine If Health and the Gibbs lab at WEHI are working to enable innovative medicines companies to more easily, quickly and cost-effectively collect real world data (RWD) alongside their oncology and haematology Medicines Access Programs.
About WEHI and the Gibbs lab
WEHI (Walter and Elize Hall Institute of Medical Research) is where the world’s brightest minds collaborate and innovate to make life-changing scientific discoveries that help people live healthier for longer. Our medical researchers have been serving the community for more than 100 years, making transformative discoveries in cancers, infectious and immune diseases, developmental disorders, and healthy ageing. The Gibbs lab focuses on clinical data, clinical trials and biomarkers in cancer. The lab employs over 50 staff, with 21 clinicians covering expertise and registries in almost all solid cancers, and has led several world-first efforts in co-ordinating national trial activity. Find out more at www.wehi.edu.au
Jason Macey, Imagine If Health Founder & CEO
Many current applications rely on slow, manual integration of datasets, rather than the access to application programming interfaces (APIs) that allow the seamless linkage between different sources of data.
The integration of The Gibbs Labs RWD collection study into an active Medicines Access Program operating on the Imagine If Health platform enables the compliant collection of existing structured patient data and a HCP communication channel to be fed directly into a real-world evidence collection study.
By running a real-world evidence study alongside the MAP, there can be a direct, timely and more seamless connection for prescribing doctors to participate in the RWE study, data can be collected in a timely manner, delivering value and insights back to the pharmaceutical company faster.
Here's just some of what the platform delivers:
Harness high quality, secure and compliant data already acquired through the Medicines Access Program.
Capture real-world evidence in real-time, whilst your Medicines Access Program is active.
By reducing double-handling and duplication of data capture, this is a highly cost effective research and insights tool.